echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: The efficacy and safety of ROCK-AKT dual inhibitor AT13148 for the treatment of solid tumors.

    Clin Cancer Res: The efficacy and safety of ROCK-AKT dual inhibitor AT13148 for the treatment of solid tumors.

    • Last Update: 2020-08-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    AT13148 is an oral AGC kinase inhibitor that potentially inhibits ROCK and AKT kinases.
    the previous clinical model, AT13148 showed anti-transfer and anti-proliferation activity.
    the trial was designed to evaluate the efficacy and safety of AT13148 for solid tumors.
    at AT13148: 3 times a week (Monday, Wednesday and Friday), 28 Mondays.
    recruited a total of 51 patients.
    dose of AT13148 was 5-300 mg.
    , doses of 120-180-240 mg were studied in the outpatient dose increase queue.
    limiting toxicity includes low blood pressure (300 mg), elevated pneumonia and liver enzymes (240 mg) and rash (180 mg).
    most common side effects are fatigue, nausea, headaches and low blood pressure.
    180 mg is set as the maximum tolerable dose based on tolerance.
    180 mg dose, the average Cmax and APC were 400 nmol/L and 13,000 nmol/L/hour, respectively;
    conclusion: AT13148 is the first double-effective ROCK-AKT inhibitor to be studied for the treatment of solid tumors.
    the narrow therapeutic index and pharmacodiodynamics lead to the further development of the compound is not recommended.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.